Medicus Pharma Ltd. Common Stock (MDCX) Stock Score, Valuation & Financial Research

Medicus Pharma Ltd. Common Stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for MDCX

Medicus Pharma Ltd. Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 0.09. These figures are a research snapshot, not a buy or sell recommendation.

What Medicus Pharma Ltd. Common Stock does

Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Medicus Pharma Ltd. is a clinical-stage, multi-strategy life sciences company that operates by investing in and accelerating the clinical development of novel therapeutic assets. The company does not currently generate commercial revenue from product sales, as its primary activities are focused on research, development, and clinical trials for its pipeline candidates.

Products and services

  • The company is developing a clinical pipeline of therapeutic assets across dermatology, urology, and oncology, including its lead candidate SkinJect for dermatological conditions.

Customer types

Healthcare providers and patients (future potential).

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company engages third-party contract research organizations to manage and conduct its clinical trials. Source

Business strengths to evaluate

  • Clinical pipeline in dermatology, urology, and oncology Source

Business risks and research considerations

  • Clinical trial failure and regulatory approval uncertainty Source
  • Requirement for additional capital to fund operations Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

MDCX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.09
Market capitalization:
5.86M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -39.15M
Free cash flow:
USD -22.78M
Cash:
USD 10.7M
Total debt:
USD 15.25M
EPS:
USD -1.62

What stands out

  • Free cash flow is USD -22.78M, negative for the stored period.
  • The balance sheet shows USD 10.7M of cash versus USD 15.25M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 4.56M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for MDCX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can MDCX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does MDCX's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for MDCX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of MDCX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-05.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research MDCX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.